Beta Drugs Fund Raise of ₹48.58 Cr

Beta Drugs Other Announcement

Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.

Beta Drugs Earnings Call Transcript: Key Takeaways

Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.

Call

Guides 25% growth

Beta Drugs Investor Presentation: Key Takeaways

Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.

Beta Drugs Q2 FY27 Results: Net Profit ₹185,507,075 Cr, Up 51.8% YoY

Beta Drugs Ltd reported revenue from operations of ₹1,374,887,594 Cr (+33.0% YoY) and net profit of ₹185,507,075 Cr (+51.8% YoY) for Q2 FY27.

Key figure

Net profit ₹185,507,075 Cr · +51.8% YoY

Beta Drugs Board Meeting Date

Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.

Beta Drugs Annual General Meeting

Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.

MosChip Technologies Fund Raise of ₹112.2 Cr

MosChip Technologies approved a preferential issue of 50,50,686 equity shares at Rs.222 to 69 investors, raising about Rs.112.19 Crore. The board approval covers the fund raise, with an AGM/postal ballot dated 25 November 2026.

Value

₹112.2 Cr

Cholamandalam Investment & Finance Company Fund Raise

Cholamandalam's board approved a Qualified Institutions Placement fund raise on 28 October 2026, subject to shareholder postal ballot. The quantum, price and terms remain undetermined.

Bodhi Tree Multimedia Fund Raise

Bodhi Tree Multimedia's EOGM on October 28, 2026, sought approval for a qualified institutions placement. The filing states no issue size.

Avalon Technologies Fund Raise of ₹425 Cr

Avalon Technologies' board approved a preferential warrant issue to Zollner Elektronik AG worth about ₹425 Crore. Shareholder approval is required at an EGM on 21 November 2026.

Value

₹425.0 Cr

Execution

Warrants exercisable within 18 months from allotment

Sealmatic India Fund Raise of ₹15.01 Cr

Sealmatic India's board approved a ₹15.01 Crore preferential issue of 3,61,620 equity shares at ₹415 to two non-promoter investors. Shareholder approval at EGM is pending.

Value

₹15.01 Cr

Sky Gold and Diamonds Fund Raise of ₹1,800 Cr

Sky Gold and Diamonds' EGM on 18 November 2026 seeks approval to raise up to ₹1,800 crore via equity-linked securities. Remote e-voting closes 17 November 2026.

Value

₹1,800 Cr